Stock Screener App

Frei -

Installieren

0.9478

3.66% -0.0394

Tempest Therapeutics Inc (TPST)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt TPST? Forum Prognose Aktiensplit

Tempest Therapeutics Inc Aktie (TPST) Neueste Nachrichten

Tempest Therapeutics secures $50M equity purchase agreement with Lincoln Park - scanx.trade

Tempest Therapeutics CEO to present at H.C. Wainwright Global Investment Conference - Bitget

A biotech CEO will speak Sept. 15; Tempest will archive the webcast - Stock Titan

Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire

Tempest Therapeutics, Inc. SEC Filing (Sep 1, 2026) - Stock Titan

Tempest Therapeutics (TPST) Slips 1.85% to $1.06 as Shares Test Support at $1.01Cup and Handle - siam.in

Tempest TherapeuticsJustin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1SEC Filing - TradingView

Tempest (TPST) Results at a Glance: Reported EPS Misses Expectations at the Close; Trading Move: The Stock Records a 1.96% Increase in Latest TradingProfit Guidance Range - vinanet.vn

Tempest Therapeutics files prospectus for sale of 8.9 million shares - scanx.trade

Tempest Therapeutics (NASDAQ: TPST) lines up $50M stock facility that may heavily dilute holders - Stock Titan

Tempest (TPST) Results Versus Estimates: The EPS Result Is Below Expectation in Latest Trading; Latest Reaction: The Stock Loses 4.58% in the Available RecordProfit Recovery Report - vinanet.vn

Tempest partners Senlang to advance TPST-4003 in China trial - scanx.trade

Form 8K Tempest Therapeutics Inc For: 18 August By Investing.com - Investing.com South Africa

Tempest Therapeutics adjourns special meeting, sets new date for stockholder vote - Investing.com

Tempest Therapeutics Adjourns Special Stockholder Meeting Again - TipRanks

TPST Q1 2026 Earnings: Wider-Than-Expected Losses as Shares Gain 11.33%Balance Sheet Strength - vinanet.vn

Tempest Therapeutics (TPST) Stock Forum and Discussion - Moomoo

TPST Q1 2026 Earnings: EPS Deeply Misses Estimates as No Revenue ReportedPositive Surprise Momentum - Vinanet

TPST Q1 2026 Earnings: Clinical-Stage Biotech Reports Deep EPS Miss as Shares Slide 13.25%EPS Surprise History - vinanet.vn

Tempest Therapeutics Cash Drops to $0.8M Amid Recent Asset Acquisition - Minichart

Tempest Therapeutics Secures Up to $50 Million Equity Facility From Lincoln Park - Minichart

Tempest Therapeutics Cash Drops to $0.8 Million, Raising Going-Concern Risk - Minichart

Form 8K Tempest Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria

Tempest Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Tempest Therapeutics Secures Flexible $50 Million Equity Facility - TipRanks

Tempest Therapeutics Q2 loss narrows to $5.2m; advances CAR-T pipeline - scanx.trade

Tempest Therapeutics (TPST) expands CAR-T pipeline amid $32.9M loss and cash strain - Stock Titan

Tempest Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors - Quiver Quantitative

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance

Tempest Therapeutics Inc (TPST) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits

Tempest Therapeutics (TPST) Surges 13% as Biotech Momentum Builds Above Key SupportAnalyst Downgrade Signals - vinanet.vn

Tempest Therapeutics Inc expected to post a loss of 30 cents a shareEarnings Preview - TradingView

Tempest Therapeutics (TPST) Gains 3% as Biotech Stock Holds Ground Above $0.86 SupportAnchored VWAP - dars.gov.et

Tempest Therapeutics (TPST) Slides to $0.86, Testing Support Near $0.82Range Breakout - vinanet.vn

Tempest Therapeutics (TPST) Shows Modest Uptick, Holding Above Key SupportPrice Target - vinanet.vn

Tempest Therapeutics Inc (TPST) Institutional Confidence - TradingKey

Tempest Therapeutics Adjourns Vote on Governance Changes - TipRanks

Tempest Therapeutics Inc (TPST) Cash Flow - TradingKey

TPST|Tempest Therapeutics Inc|Price:0.942|Chg%:+0.016 - TradingKey

Tempest Therapeutics Inc (TPST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

TradingKey - TradingKey

Tempest Therapeutics Inc (TPST) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Tempest Therapeutics, Inc. Revenue Breakdown – NASDAQ:TPST - TradingView

Tempest Therapeutics Inc (TPST) Valuation: PE, PB & Fair Value Analysis - TradingKey

TPST Q1 2026 Earnings: Wide EPS Miss Highlights Cash Burn ChallengesEarnings Growth Forecast - vinanet.vn

Tempest Therapeutics (TPST) Slightly Declines as Stock Nears Support LevelBuy Signal Reports - dars.gov.et

Tempest Therapeutics inks China in vivo CAR-T deal - TipRanks

Tempest Therapeutics, Inc. and Heibei Senlang Biotechnology Co., Ltd. Enter into Product Development and Investigator-Initiated Trial Collaboration Agreement - marketscreener.com

Tempest Therapeutics (TPST) Pulls Back to $0.97, Testing Key SupportSign of Weakness - dars.gov.et

Tempest Therapeutics Announces Strategic Partnership with Senlang to Advance TPST-4003 into First-in-Human Study in Autoimmune Diseases - Quiver Quantitative

Tempest Announces Development Collaboration with Senlang - GlobeNewswire

TPST Q1 2026 Earnings: Wide EPS Miss Highlights Ongoing Clinical-Stage LossesRevenue Per Share - vinanet.vn

Tempest Therapeutics (TPST) Inches Higher Near Resistance as Trading Remains SubduedDeath Cross - vinanet.vn

Tempest Therapeutics (TPST) plans vote on supermajority and written-consent changes - Stock Titan

William Drake Richey Net Worth (2026) - GuruFocus

Tempest advances next-generation in vivo CAR T pipeline - BioWorld News

Tempest Therapeutics (TPST) Slips 3.74% as Stock Tests Key Support ZonePut Call Ratio - vinanet.vn

Tempest plans trial of in vivo CAR-T candidate for autoimmune diseases By Investing.com - Investing.com South Africa

Tempest Therapeutics Announces Advancement of Lead In Vivo CAR-T Candidate TPST-4003 into Planned Autoimmune Disease Trial - Quiver Quantitative

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, - GlobeNewswire

RPRX

$60.38

0.61%

INSM

$129.81

3.65%

ROIV

$41.77

0.78%

ALNY

$255.78

1.73%

ONC

$350.10

0.47%

RVMD

$210.19

1.38%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters